Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-061023
Filing Date
2025-04-30
Accepted
2025-04-30 16:04:58
Documents
19
Period of Report
2025-06-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A ntla-20250430.htm   iXBRL DEF 14A 3058097
2 GRAPHIC img110898100_0.jpg GRAPHIC 81081
3 GRAPHIC img110898100_1.jpg GRAPHIC 81081
4 GRAPHIC img110898100_2.jpg GRAPHIC 86314
5 GRAPHIC img110898100_3.jpg GRAPHIC 36349
6 GRAPHIC img110898100_4.jpg GRAPHIC 950823
7 GRAPHIC img110898100_5.jpg GRAPHIC 677358
  Complete submission text file 0000950170-25-061023.txt   8792160

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20250430.xsd EX-101.SCH 26685
21 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20250430_htm.xml XML 191279
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37766 | Film No.: 25894878
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)